| | |
| Lundbeck appeals against EU Commission fine Sunday, Sep 01, 2013 11:16 PM PDT COPENHAGEN (Reuters) - Danish pharmaceutical group Lundbeck has filed an appeal against a 93.8 million euros ($123.7 million) fine by the European Commission for deals with rivals to block the supply of generic versions of its citalopra anti-depressant to the market. Lundbeck said in a statement that the aim of the appeal was to have the decision annulled or the fine reduced. The company said it expects a decision on the appeal within two to three years. ($1 = 0.7584 euros) (Reporting by Copenhagen Newsroom; Editing by David Goodman) Full Story | Top |
| Doctors get good and bad safety news on diabetes drugs Sunday, Sep 01, 2013 11:01 PM PDT By Ben Hirschler AMSTERDAM (Reuters) - Diabetes pills known as DPP-4 therapies got a mixed safety report on Monday as studies showed they did not raise the risk of heart attacks but might be linked to heart failure, where the heart fails to pump blood adequately. Reassuringly, the medicines were not associated with increased rates of either inflammation of the pancreas or cancer - something that has been a worry in the past. However, in the case of AstraZeneca and Bristol-Myers Squibb's approved drug Onglyza, there was a small increase in hospitalizations for heart failure. ... Full Story | Top |
| New formulation of Roche's Herceptin wins EU approval Sunday, Sep 01, 2013 10:17 PM PDT ZURICH (Reuters) - Swiss drugmaker Roche said on Monday the European Commission had approved a new formulation of its breast cancer drug Herceptin which allows the medicine to be administered more quickly. Roche said it had won approval for a new injectable version of Herceptin which cuts down treatment time to just two to five minutes. It currently takes between 30 to 90 minutes to administer the drug intravenously. ... Full Story | Top |
| Parents' ADHD goals tied to treatment choices: study Sunday, Sep 01, 2013 09:39 PM PDT By Genevra Pittman NEW YORK (Reuters Health) - Parents' goals and concerns for their children with attention-deficit/hyperactivity disorder may influence their decision to start behavior therapy or medication, according to a new study that researchers say supports a shared decision-making approach to ADHD treatment. Researchers found parents who were focused on their child's academic achievement were twice as likely to have the child started on medications, which include Adderall and Ritalin, as other parents. ... Full Story | Top |
| Florida college band marches for first time since hazing death Sunday, Sep 01, 2013 05:16 PM PDT MIAMI (Reuters) - Florida A&M University's marching band returned to the football field on Sunday, nearly two years after the beating death of a drum major in a hazing incident led to its suspension. "Bands to make you dance. It's time!" an announcer said as the band kicked off a seven-minute halftime show at the school's home opener against Mississippi Valley State. A moment of silence was held for Robert Champion before the game in Orlando, Florida. ... Full Story | Top |
| Bigger and healthier: European men grow 11cm in a century Sunday, Sep 01, 2013 04:21 PM PDT  By Kate Kelland LONDON (Reuters) - The average height of European men grew by a surprising 11 centimeters from the early 1870s to 1980, reflecting significant improvements in health across the region, according to new research published on Monday. Contrary to expectations, the study also found that average height accelerated in the period spanning the two World Wars and the Great Depression, when poverty, food rationing and hardship of war might have been expected to limit people's growth. ... Full Story | Top |
| Life expectancy gap growing between rich/poor world women: WHO Sunday, Sep 01, 2013 03:14 PM PDT  By Stephanie Nebehay GENEVA (Reuters) - Life expectancy for women at 50 has improved, but the gap between poor and rich countries is growing and could worsen without better detection and treatment of cardiovascular disease and cancers, the World Health Organization (WHO) said on Monday. A WHO study, one of the first to analyze the causes of death of older women, found that in wealthier countries deaths from noncommunicable diseases has fallen dramatically in recent decades, especially from cancers of the stomach, colon, breast and cervix. ... Full Story | Top |
| Japan government abandons hands-off approach to Fukushima clean-up Sunday, Sep 01, 2013 02:12 PM PDT  By Linda Sieg and Mari Saito TOKYO (Reuters) - Japan's government is moving to take a more direct role in the clean-up of the wrecked Fukushima nuclear plant, as concerns grow over the ability of embattled operator Tokyo Electric to handle the legacy of the worst atomic disaster in a quarter century. The concerns have also revived debate about the future of Tokyo Electric Power Co (Tepco) itself, including early-stage proposals to put its toxic nuclear assets under government control and leave the rest of the company as a provider of power to the nation's biggest economic region. ... Full Story | Top |
| South Africa's Mandela back home after long hospital stay Sunday, Sep 01, 2013 06:08 AM PDT  By Peroshni Govender JOHANNESBURG (Reuters) - Anti-apartheid leader and former South African President Nelson Mandela returned to his home on Sunday where he will continue to receive intensive care after three months in hospital with a lung ailment. Mandela, 95, had spent 87 days in a Pretoria hospital after he was rushed there in early June suffering from a recurring infection of the lungs, a legacy of the nearly three decades he spent in jail under apartheid. "Madiba's condition remains critical and is at times unstable. ... Full Story | Top |
| Isis heart drug leads to big reduction in blood fat Sunday, Sep 01, 2013 03:16 AM PDT AMSTERDAM (Reuters) - An experimental drug from Isis Pharmaceuticals produced a sharp reduction in levels of triglycerides, a type of fat in the blood that increases the risk of heart disease, a small mid-stage trial showed. Codenamed ISIS-APOCIIIRx, the drug is attracting increased attention from investors who believe it could be a big money spinner for the U.S. biotech company. It is designed for patients with very high to severely high triglyceride levels. ... Full Story | Top |
| New Daiichi drug vies for slice of clot prevention market Sunday, Sep 01, 2013 01:15 AM PDT  By Ben Hirschler AMSTERDAM (Reuters) - A new blood clot preventer from Daiichi Sankyo proved as effective as widely used warfarin in treating a dangerous condition known as venous thromboembolism and caused less bleeding, a large clinical trial found. The Japanese drugmaker hopes the finding will help it take on rivals including Bayer, Johnson & Johnson, Pfizer and Bristol-Myers Squibb in a growing market for novel pills to prevent blood clots, especially as the drug appears to work best in sicker patients. ... Full Story | Top |
|
No comments:
Post a Comment